Atlas Venture Associates Ix, LLC Coherus Bio Sciences, Inc. Transaction History
Atlas Venture Associates Ix, LLC
- $11.3 Million
- Q3 2023
A detailed history of Atlas Venture Associates Ix, LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Atlas Venture Associates Ix, LLC holds 568,408 shares of CHRS stock, worth $591,144. This represents 18.88% of its overall portfolio holdings.
Number of Shares
568,408Holding current value
$591,144% of portfolio
18.88%Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
143Shares Held
82.6MCall Options Held
79.1KPut Options Held
100K-
Black Rock Inc. New York, NY11.8MShares$12.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$11 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$10.8 Million0.53% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U05.82MShares$6.05 Million0.05% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$3.16 Million0.3% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $80.8M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...